AstraZeneca’s Enhertu breast cancer trial shows ‘unprecedented’ results

AstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday. The findings, presented in Chicago at the annual meeting […]